Orfadin Suspension
NDC 66658-204
Product Information
Orfadin (nitisinone) is a NDA-approved product labeled by Swedish Orphan Biovitrum Ab (publ). Nitisinone is used to treat a certain inherited disorder (hereditary tyrosinemia type 1, also known as HT-1). It is supplied as a suspension for oral administration. This product entry covers the primary NDC 66658-204 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
Code Structure Chart
Product Details
What is NDC 66658-204?
What are the uses of this product?
What are Active Ingredients of this product?
- NITISINONE 4 mg/mL - used in treatment of hereditary tyrosinaemia type I
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- NITISINONE (UNII: K5BN214699)
- NITISINONE (UNII: K5BN214699) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- HYPROMELLOSES (UNII: 3NXW29V3WO)
- GLYCERIN (UNII: PDC6A3C0OX)
- POLYSORBATE 80 (UNII: 6OZP39ZG8H)
- SODIUM BENZOATE (UNII: OJ245FE5EU)
- CITRIC ACID MONOHYDRATE (UNII: 2968PHW8QP)
- TRISODIUM CITRATE DIHYDRATE (UNII: B22547B95K)
- WATER (UNII: 059QF0KO0R)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 1790310 - nitisinone 4 MG in 1 mL Oral Suspension
- RxCUI: 1790310 - nitisinone 4 MG/ML Oral Suspension
- RxCUI: 1790310 - nitisinone 4 MG per 1 ML Oral Suspension
- RxCUI: 1790317 - Orfadin 4 MG in 1 mL Oral Suspension
- RxCUI: 1790317 - nitisinone 4 MG/ML Oral Suspension [Orfadin]
Which are the Pharmacologic Classes of this product?
- 4-Hydroxyphenyl-Pyruvate Dioxygenase Inhibitor - [EPC] (Established Pharmacologic Class)
- Cytochrome P450 2C9 Inhibitors - [MoA] (Mechanism of Action)
- Cytochrome P450 2E1 Inducers - [MoA] (Mechanism of Action)
- Hydroxyphenylpyruvate Dioxygenase Inhibitors - [MoA] (Mechanism of Action)
- Organic Anion Transporter 1 Inhibitors - [MoA] (Mechanism of Action)
- Organic Anion Transporter 3 Inhibitors - [MoA] (Mechanism of Action)
* Please review the full disclaimer at the bottom of this page.